Business Wire

NY-IFF

11.1.2023 22:16:44 CET | Business Wire | Press release

Share
IFF Recognized for Achieving Sustainability Leadership Throughout Transformational Year

IFF (NYSE:IFF) today announced it has qualified for the third consecutive year as a constituent of the Dow Jones Sustainability Indices (DJSI), a family of benchmarks widely regarded as one of the world’s leading tools for investors to integrate sustainability considerations into their portfolios to increase long-term shareholder value. Named to both the 2022 World Index and the North America Index, IFF is the only company in its industry to be included.

The S&P Global Corporate Sustainability Assessment (CSA) serves as the basis for the ESG scores that power the DJSI and its prestigious list of selected companies. IFF’s total CSA score places the Company among the top 10 percent of sustainability performers in the world, as assessed from among the 2,500 largest companies in the S&P Global Broad Market Index (BMI). Similarly, IFF ranks among the top 20 percent of the 600 largest companies in the S&P Global BMI in North America.

The distinction of achieving an annual place on the DJSI – and even increasing its score from the prior year – underscores IFF’s ongoing leadership position in environmental, social and governance (ESG) management, despite significantly increasing its size and complexity following the merger with DuPont’s Nutrition & Biosciences division in 2021. The Company’s CSA disclosures scored in 2022 were the first to reflect its post-merger performance and outcomes, including those based on an increase from nearly 14,000 employees to more than 24,000, and an expanded global footprint.

IFF was also recognized for leadership in corporate transparency and performance on climate change by global environmental non-profit CDP, securing a place on its 2022 ‘A List’ for climate change for the eighth consecutive year. Based on IFF’s post-merger data reported through CDP’s 2022 Climate Change questionnaire, IFF is one of a small number of companies out of nearly 15,000 scored that were named to the ‘A List’ for climate change, based on its actions to reduce emissions, mitigate climate risks and develop the low-carbon economy. IFF also received an “A-“ in CDP’s other two categories for action to protect water security risks and forests.

“We’re very proud to be recognized by S&P Global and CDP for our ESG excellence in 2022,” said Frank Clyburn, CEO, IFF. “We credit these achievements to the laser focus of our global team—striving to be the most sustainable company we can be—guided by our ambitious Do More Good Plan. We know we have more work to do in 2023 and beyond, but these external validations continue to inspire us and are a reminder that we’re heading in the right direction.”

IFF’s Do More Good Plan is a comprehensive ESG roadmap aligned with the Company’s purpose of applying science and creativity for a better world, organized by the four strategic focus areas of Sustainable Solutions, Climate & Planetary Health, Equity & Wellbeing and Transparency & Accountability.

The 2022 DJSI and CDP recognitions follow several other competitive ESG ratings IFF received during the year, including being:

  • Awarded the 2022 EcoVadis Platinum sustainability rating for the second time, placing IFF among the top 1% of companies assessed;
  • Named for the first time to the 2022 Bloomberg Gender Equality Index for its commitment to transparency and setting a new standard in gender-related data reporting; and
  • Recertified for the second consecutive year by the Economic Dividends for Gender Equality (EDGE) at the Move level globally for its commitment to workplace diversity and intersectional issues.

Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005902/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Askey and Canoga Perkins Announce Strategic Collaboration at MWC Barcelona to Deliver Rapid-Deploy 5G Critical Communications Solutions27.3.2026 12:00:00 CET | Press release

Askeyand Canoga Perkinsannounced at Mobile World Congress Barcelona a Global Partnership to Deliver SyncMetra® Network Connectivity Solution, combining Canoga Perkins’ software-defined, IT-operated private 5G network transport along with Askey’s carrier-grade 5G radio access technology. At MWC Barcelona 2026, Askey Computer Corporation and Canoga Perkins announced a strategic partnership to deploy Canoga Perkins' SyncMetra® Platform across enterprise and service provider markets with Askey. This partnership pairs Askey’s carrier-grade radio access capabilities with Canoga Perkins’ industry-leading time-sensitive networking (TSN) and synchronization technology, enabling customers to simplify deployment of ultra-low-latency, highly reliable network services for 5G, edge compute, industrial automation, and mission-critical enterprise applications. The partnership enables joint go-to-market efforts, integrated product offerings, and expanded access to SyncMetra through Askey’s sales channe

SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results27.3.2026 11:40:00 CET | Press release

Q4 EPS more than doubles to $0.14 as profitability improves significantly year over year SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial results for the fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025). Fourth Quarter 2025 Highlights Total revenues were $40 million, representing an 11% year-over-year decrease. Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.14 for the three months ended December 31, 2025, representing 133% year-over-year increase. EBITDA1, which is calculated by adding depreciation and amo

NIQ Redefines Packaging Intelligence with Monthly, Harmonized Global Performance Visibility27.3.2026 11:00:00 CET | Press release

NIQ’s new solution brings unprecedented clarity into package types, materials, and true consumption across markets, closing critical industry gaps NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of its Packaging Strategic Planner Global (SPG) Solution, the first harmonized global platform to deliver monthly visibility into packaging performance across materials, formats, and pack configurations. As packaging innovation accelerates, many organizations continue to rely on fragmented or annual data to inform packaging decisions. The Packaging SPG Solution closes this gap by providing real-time data delivered monthly across regions, enabling brands and packaging partners to uncover trends, grow revenue, and strengthen relationships with CPG and retail partners. Key Highlights: New monthly global packaging tracking capability Coverage across 200+ categories Visibility into 30+ package types and 20 package materials 10+ markets at launch, expanding

European DataWarehouse Claims Its First “Fintech Provider of the Year” Award and a Sixth “Data Provider of the Year” Title at GlobalCapital’s 2026 European Securitisation Awards27.3.2026 08:47:00 CET | Press release

European DataWarehouse (EDW) is pleased to announce that it has been named both “Data Provider of the Year” and “Fintech Provider of the Year” at the 2026 GlobalCapital European Securitization Awards in London. The award ceremony recognises outstanding achievements in European structured finance, with winners selected by popular vote from across the industry. As defined by GlobalCapital, the programme celebrates “the very best in the market, as chosen by the market.” This latest recognition marks the sixth time that EDW has received the prestigious Data Provider of the Year award, having previously been honoured in 2019, 2022, 2023, 2024 and 2025, reaffirming its long-standing commitment to transparency, data quality and innovation in European securitisation. Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “ Winning this award for the sixth time highlights the continued trust the European securitisation market places in EDW. Transparency, data quality and reliabili

Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye